Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 7;11(10):e052138. doi: 10.1136/bmjopen-2021-052138

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

iBox^#1 scores at 1 year after randomisation and projected allograft survival. (A) Mean iBox^#1 scores in the EVR+rCNI and MPA+sCNI arms at 1 year. (B) Projected allograft survival in EVR+rCNI arm (blue line) and MPA+sCNI arm (red line). The black dotted line corresponds to the 10% inferiority margin. The duration of TRANSFORM is the time between randomisation and the endpoint of the TRANSFORM Study (1 year post-randomisation). The projected kidney allograft survival takes into account the event (death-censored graft loss) that occurred during the duration of TRANSFORM Study. EVR, everolimus, iBox, integrative Box; MPA, mycophenolic acid; rCNI, reduced-exposure calcineurin inhibitor; sCNI, standard-exposure calcineurin inhibitor.